170 related articles for article (PubMed ID: 10920882)
21. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Liu X
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
[TBL] [Abstract][Full Text] [Related]
23. [The experimental treatment of laryngeal cancer using local draining lymph node lymphocytes].
Wu Y; Guo M
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(1):26-8. PubMed ID: 9275399
[TBL] [Abstract][Full Text] [Related]
24. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer.
Chang AE; Li Q; Jiang G; Teknos TN; Chepeha DB; Bradford CR
Head Neck; 2003 Mar; 25(3):198-209. PubMed ID: 12599287
[TBL] [Abstract][Full Text] [Related]
25. A new approach to the treatment of malignant effusion.
Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
[TBL] [Abstract][Full Text] [Related]
26. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
[TBL] [Abstract][Full Text] [Related]
27. [Comparative study on cytotoxicity of lymphocytes from different tissues in laryngeal cancer].
An W
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):292-4, 314-5. PubMed ID: 8192933
[TBL] [Abstract][Full Text] [Related]
28. [Adoptive immunotherapy in patients with medulloblastoma by LAK cells].
Shimizu K; Tamura K; Yamada M; Okamoto Y; Miyao Y; Park K; Matsui Y; Hayakawa T; Takimoto H; Mogami H
No To Shinkei; 1989 Oct; 41(10):991-5. PubMed ID: 2605046
[TBL] [Abstract][Full Text] [Related]
29. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
[TBL] [Abstract][Full Text] [Related]
30. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
Nomura K; Fujioka T
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
[TBL] [Abstract][Full Text] [Related]
31. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
Mao G; Gao Z; Wang Q
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
[TBL] [Abstract][Full Text] [Related]
32. [The effect of MPS on LAK cell growth and its cytotoxic activity against laryngeal cancer (HEP-2)].
Wang J; Zhu X; Chen J
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(5):283-6. PubMed ID: 9642362
[TBL] [Abstract][Full Text] [Related]
33. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
[TBL] [Abstract][Full Text] [Related]
34. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow up].
Han DM; Huang ZG; Zhang W; Yu ZK; Wang Q; Ni X; Chen XH; Pan JH; Wang H
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2029-32. PubMed ID: 14703409
[TBL] [Abstract][Full Text] [Related]
36. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
[TBL] [Abstract][Full Text] [Related]
37. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.
Blancher A; Roubinet F; Grancher AS; Tremoulet M; Bonaté A; Delisle MB; Calot JP; Pourreau C; Franks C; Ducos J
Eur Cytokine Netw; 1993; 4(5):331-41. PubMed ID: 8117934
[TBL] [Abstract][Full Text] [Related]
38. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
[TBL] [Abstract][Full Text] [Related]
39. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2.
Sacchi M; Vitolo D; Sedlmayr P; Rabinowich H; Johnson JT; Herberman RB; Whiteside TL
Int J Cancer; 1991 Mar; 47(5):784-91. PubMed ID: 2004859
[TBL] [Abstract][Full Text] [Related]
40. Effect of tumor irradiation on the uptake of lymphokine-activated killer cells in a murine tumor model.
Munshi NC; Williams JR
Cancer Res; 1994 Apr; 54(7):1657-9. PubMed ID: 8137277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
